Polpharma Biologics, Fresenius Kabi License Vedolizumab Biosimilar
Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016,...
